https://www.businessline.global/takedas-maribavir-phase-3-clinical-trial-met-primary-endpoint-of-superiority-to-conventional-antiviral-therapy-in-transplant-recipients-with-refractory-with-or-without-resistance-cytomegalo/press-release/